Skip to main content
Signal8
Launch Terminal
Ede-Golightly James profile photo

James Ede-Golightly

CIK: 0002048873

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Silence Therapeutics plc logo
SLN

Silence Therapeutics plc

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Silence Therapeutics plc logo
    SLN

    Silence Therapeutics plc

    Jan 2, 2026
    Award(A)

    Share Option (Right to Buy)

    Direct
    90K shares-
  • Silence Therapeutics plc logo
    SLN

    Silence Therapeutics plc

    Dec 22, 2025
    Award(A)

    Share Option (Right to Buy)

    Direct
    90K shares-
  • Silence Therapeutics plc logo
    SLN

    Silence Therapeutics plc

    Jan 2, 2025
    Award(A)

    Share Option (Right to Buy)

    Direct
    48K shares-

1-3 of 3

About Ede-Golightly James

Ede-Golightly James (SEC CIK 0002048873) files insider reports with the SEC as Director of Silence Therapeutics plc (SLN).

Signal8 holds 5 ownership filings by Ede-Golightly James (2 Form 3, 3 Form 4), filed between Jan 2, 2025 and Jan 6, 2026. Those filings report 3 transactions, from Jan 2, 2025 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ede-Golightly James's filings is in LONDON, X0.

Recent filings by Ede-Golightly James

  • Jan 2, 2026: Grant or award of SLN derivative securities (Form 4, code A).
  • Dec 22, 2025: Grant or award of SLN derivative securities (Form 4, code A).
  • Jan 2, 2025: Grant or award of SLN derivative securities (Form 4, code A).

Other insiders filing for Silence Therapeutics plc (SLN)

How to read Form 4 transaction codes